Cognitive Decline & Vascular Dementia: Vascular Context and EECP Evidence

EVIDENCE BOX — CLAIM 3

EECP for Cognitive Decline & Vascular Dementia: No direct evidence

Evidence tier: No direct evidence for vascular dementia The source check did not identify a peer-reviewed human EECP efficacy study enrolling a cohort diagnosed with vascular dementia and testing whether EECP improves cognition, daily function, disease progression, or vascular-dementia outcomes. Therefore, there is no direct human EECP efficacy evidence for the exact vascular-dementia component of this page’s condition name. There are studies in adjacent populations—post-stroke cognitive impairment, general mild cognitive impairment, and Alzheimer-related mild cognitive impairment or mild Alzheimer-type dementia. These do not become evidence for vascular dementia merely because cognition or vascular measures were included. The limits below are part of the evidence conclusion, not fine print.

| Evidence item | What it studied | Strict inference limit | |---|---|---| | Post-stroke cognitive impairment study | A retrospective, single-hospital analysis of 60 people with mild cognitive impairment after stroke compared EECP plus atorvastatin (n=30) with atorvastatin alone (n=30). EECP was delivered for 36 sessions over six weeks; atorvastatin was given for 24 weeks. The report measured MMSE, MoCA, activities of daily living, biomarkers, and cerebral arterial Doppler indices. | This was not a vascular-dementia cohort. It was retrospective, nonrandomized, unblinded, small, and used a combined EECP-plus-atorvastatin intervention versus atorvastatin alone; there was no sham control. The report does not establish an EECP-alone effect, durable dementia outcome, prevention, reversal, or applicability to vascular dementia. The authors identify retrospective design and small sample size as limitations and call for prospective multicenter study. | | Mild cognitive impairment pilot | A four-person safety/feasibility pilot in people with clinical dementia rating 0.5 (mild cognitive impairment) delivered 35 EECP sessions and measured regional cerebral blood flow and cognitive measures. The study used the Hachinski score to exclude severe vascular dementia; it was not a vascular-dementia trial. | Sample size was four, there was no randomized or sham comparator, and cognition was underpowered; only three participants had both baseline and post-treatment cognitive scores. Its exploratory cerebral-perfusion findings cannot demonstrate cognitive benefit, disease modification, or efficacy in vascular dementia. | | Alzheimer-related randomized sham-controlled trial | The completed 190-participant Renew NCP-5 trial randomized people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer-type dementia to treatment or sham. A 2023 meeting abstract reported outcomes in an MCI/mild Alzheimer’s disease population. | This is not a vascular-dementia study. The ClinicalTrials.gov record explicitly excludes clinically evident stroke and substantial concomitant cerebrovascular disease, including multiple/extensive infarcts or severe white-matter hyperintensity burden. A vascular-dementia cognitive scale was an outcome instrument; the use of that instrument does not make the enrolled population vascular dementia. | | Earlier completed trial registration | ClinicalTrials.gov record NCT01659398 was a completed, eight-person, early-phase, nonrandomized, open-label study in mild cognitive impairment; it lists no posted results. Its eligibility criteria excluded severe vascular disease established by the Hachinski Ischemic Index. | A trial registration is not proof of efficacy. This record does not provide published results and did not enroll a diagnosed vascular-dementia cohort. |^{[9][9][10][10][12][13][12][12][13][11][11]}

Permitted evidence statement: Direct human EECP efficacy evidence for vascular dementia was not identified in this source check. Adjacent studies in post-stroke cognitive impairment, MCI, and Alzheimer-related cognitive impairment cannot establish efficacy for vascular dementia.–^[9][13]

Not permitted: Do not say or imply that EECP treats, cures, reverses, slows, prevents, or is appropriate for vascular dementia; that a peripheral endothelial or flow-mediated-dilation finding proves cerebral benefit; that a post-stroke cognitive-impairment study is a vascular-dementia study; or that a registry listing, protocol, outcome-scale name, or adjacent Alzheimer-related trial establishes vascular-dementia efficacy.

A ClinicalTrials.gov search using Vascular Dementia and Enhanced External Counterpulsation returned one completed EECP record, NCT01659398, but that record’s listed condition is mild cognitive impairment, it enrolled eight participants, and no results are posted. This registry observation is a search finding, not a claim that all possible research has been exhaustively located or that a registry entry demonstrates benefit.^[11]